Osteoarthritis vs. Osteoporosis - Complete Comparison with Treatment
These two conditions are commonly confused because both affect the skeletal system in older adults - but they are fundamentally different diseases involving different tissues, mechanisms, symptoms, and treatments.
THE CORE DISTINCTION
| Osteoarthritis (OA) | Osteoporosis |
|---|
| What is affected | Articular cartilage + joint structures | Bone mass and density (whole skeleton) |
| Basic problem | Cartilage degeneration and failed repair | Bone resorption exceeds bone formation |
| Primary mechanism | Mechanical/biomechanical stress | Metabolic bone disease |
| Pain | Yes - joint pain, activity-related | Usually none until fracture occurs |
| Fracture risk | Not primary (unless secondary to deformity) | The main clinical danger |
| Systemic disease? | No | Yes (systemic bone loss) |
PART 1: OSTEOARTHRITIS (OA)
Definition
OA (degenerative joint disease) is characterized by failed repair of synovial joint tissues after intra-articular stress, resulting in cartilage breakdown and bone changes that cause pain, stiffness, and functional disability. It is the most common disease of joints.
- Goldman-Cecil Medicine: "The resulting breakdown of cartilage and bone can lead to symptoms of pain, stiffness, and functional disability. However, synovial joint pathology and structural changes on imaging may correlate poorly with patient-reported symptoms."
Epidemiology
- Affects >50 million people worldwide; women disproportionately affected
- Prevalence rises exponentially after age 50; ~40% of people over 70 are affected
- Primary OA (idiopathic): appears without cause, as an aging phenomenon - oligoarticular, affecting weight-bearing joints
- Secondary OA (~5% of cases): occurs in younger people with joint deformity, prior injury, diabetes, or obesity
Pathogenesis
OA is initiated by biomechanical stress on cartilage in a genetically predisposed individual. The key sequence:
- Chondrocyte injury - mechanical/genetic insult damages chondrocytes and the extracellular matrix (Type II collagen, proteoglycans)
- Early OA - chondrocytes proliferate and attempt repair, releasing BMPs (bone morphogenetic proteins) for repair, but also MMPs (matrix metalloproteinases), PGE2, NO, and TNF that degrade collagen and proteoglycans faster than they can be repaired
- Late OA - chondrocyte dropout, apoptosis, full-thickness cartilage loss, subchondral bone damage, osteophyte formation, loose bodies ("joint mice")
Schematic of OA progression: chondrocyte injury → early OA (matrix degradation) → late OA (cartilage loss, osteophytes, subchondral changes) - Robbins & Kumar Basic Pathology
Morphology / Pathology
| Feature | Description |
|---|
| Cartilage | Fibrillation, erosion, full-thickness sloughing |
| Subchondral bone | Eburnation (polished ivory appearance) from exposed bone friction |
| Subchondral cysts | Synovial fluid forced into bone via ball-valve mechanism |
| Osteophytes | Bony outgrowths at joint margins, capped by fibrocartilage |
| Loose bodies | Dislodged cartilage/bone fragments ("joint mice") |
| Synovium | Mildly congested and fibrotic; minimal inflammation (unlike RA) |
Left: RA joint with pannus, dense synovial inflammation, bony ankylosis. Right: OA joint showing thinned cartilage, osteophytes, loose bodies, subchondral sclerosis, and subchondral cysts - Robbins & Kumar
Clinical Features
- Joint pain - worsens with use, improves with rest (early) or persists at rest (late = "night pain" = surgical indication)
- Morning stiffness - brief, typically <30 minutes (unlike RA >1 hour)
- Crepitus - grinding or clicking with movement
- Limited range of motion
- Bony enlargement - osteophytes palpable at joint margins
- Heberden nodes (osteophytes at DIP joints) and Bouchard nodes (PIP joints) - more common in women
- No systemic features (no fever, no weight loss, no fatigue)
- Spinal OA: osteophytes compressing nerve roots cause radicular pain, muscle spasms, atrophy, neurological deficits
Joints Commonly Involved
- Hips, knees (weight-bearing - most symptomatic)
- Lower lumbar and cervical vertebrae
- DIP and PIP joints of fingers
- First carpometacarpal joint (base of thumb)
- First tarsometatarsal joint (base of big toe)
- NOT typically: wrists, MCPs, ankles (these suggest inflammatory arthritis)
Diagnosis
| Test | Finding in OA |
|---|
| X-ray | Joint space narrowing, osteophytes, subchondral sclerosis, subchondral cysts |
| Blood tests | Normal - no inflammatory markers, negative RF/ANA |
| ESR/CRP | Normal or mildly elevated |
| Synovial fluid | Non-inflammatory: WBC <2000/mm³, clear, viscous |
| MRI | Best for cartilage loss assessment, bone marrow changes |
X-ray findings:
AP X-ray of right knee showing medial compartment joint space narrowing, osteophytes, and subchondral sclerosis - consistent with Kellgren-Lawrence Grade 1-2 OA
Treatment of Osteoarthritis
Non-Pharmacological (First Line)
| Approach | Details |
|---|
| Weight loss | Most impactful - reduces load on knee by 4x the weight lost |
| Exercise | Low-impact aerobic (swimming, cycling), strengthening; reduces pain and improves function |
| Physical therapy | Quadriceps strengthening for knee OA, range-of-motion exercises |
| Walking aids | Stick in opposite hand offloads the affected hip/knee |
| Joint protection | Activity modification, avoiding high-impact activities |
| Heat/Cold | For symptomatic relief |
Pharmacological
| Drug | Role | Notes |
|---|
| Paracetamol (acetaminophen) | First-line analgesic | Safe, effective for mild-moderate pain; limited anti-inflammatory effect |
| Topical NSAIDs | First-line for knee/hand OA | Diclofenac gel - effective with lower systemic side effects |
| Oral NSAIDs (ibuprofen, naproxen, celecoxib) | For moderate pain | Reduce inflammation and pain; GI risk; COX-2 inhibitors have less GI toxicity |
| Duloxetine | Central pain modulation | SNRI; useful for widespread OA pain, especially with comorbid depression/anxiety |
| Intra-articular corticosteroids | For acute flares | Short-term relief; limit to 3-4 injections/year per joint |
| Intra-articular hyaluronic acid | Viscosupplementation | Evidence is mixed; may help some patients with knee OA |
| Tramadol / weak opioids | For refractory pain | When NSAIDs contraindicated; use cautiously in elderly |
From Rosen's Emergency Medicine: "There are no treatments to prevent or halt the progression of OA. Therapies include pain management, NSAIDs to reduce inflammation, intra-articular corticosteroids, activity modification, and, for severe cases, joint replacement."
Surgical Treatment
| Procedure | Indication |
|---|
| Total joint replacement (arthroplasty) | Relentless pain (especially night pain), failure of non-operative treatment, severe limitation of ADLs |
| Osteotomy (joint realignment) | Younger patients with malalignment; delays need for replacement |
| Arthrodesis (joint fusion) | Selected joints (ankle, wrist); sacrifices movement for pain relief |
| Arthroscopy | Limited role; lavage and debridement no longer routinely recommended |
Surgical indications: pain at rest/night, limitation of daily activities, and failure of conservative treatment.
PART 2: OSTEOPOROSIS
Definition
Osteoporosis is a metabolic bone disease defined as a skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture.
- Bone strength = BMD (bone mineral density) + bone quality (architecture, turnover, mineralization, micro-damage)
- WHO Definition by T-score (BMD measured by DXA, compared to young healthy reference):
- Normal: T-score ≥ -1.0
- Osteopenia: T-score between -1.0 and -2.5
- Osteoporosis: T-score ≤ -2.5
- Severe osteoporosis: T-score ≤ -2.5 + fragility fracture
Epidemiology
- Most common metabolic bone disease
- ~50% of women and 20% of men over age 50 will have a fragility fracture in their lifetime (Caucasian populations)
- The elderly are the fastest-growing age group; yearly fragility fractures will increase substantially
- One fragility fracture dramatically increases the risk of future fractures: vertebral fracture → hip fracture risk ×2, vertebral fracture risk ×5
Pathogenesis
Osteoporosis results from an imbalance between bone resorption (osteoclast) and bone formation (osteoblast):
| Mechanism | Details |
|---|
| Peak bone mass | Achieved by ~age 30; never exceeded after this point |
| Post-menopausal | Estrogen loss → marked increase in osteoclast activity → accelerated bone resorption |
| Age-related (senile) | Decreased osteoblast function + reduced calcium absorption + secondary hyperparathyroidism |
| Glucocorticoid-induced | Most common secondary cause; reduces osteoblast activity and increases osteoclast activity |
Main Causes of Osteoporosis
Primary:
- Postmenopausal (type I)
- Senile/age-related (type II)
- Idiopathic
Secondary:
- Endocrine: hyperparathyroidism, hyperthyroidism, Cushing's syndrome, hypogonadism, diabetes mellitus
- Drugs: glucocorticoids (most common), heparin, anticonvulsants, proton pump inhibitors, aromatase inhibitors
- Nutritional: calcium/vitamin D deficiency, malabsorption, anorexia nervosa
- Inflammatory: rheumatoid arthritis, IBD
- Immobilization
Clinical Features
Osteoporosis itself is SILENT until a fracture occurs. The disease is asymptomatic until a fracture happens.
Fractures - The Clinical Presentation
| Fracture Type | Features |
|---|
| Vertebral compression fracture | Acute back pain after minimal trauma; resolves in 6-8 weeks; or completely asymptomatic (30%+). Multiple fractures → progressive loss of height, increased kyphosis ("dowager's hump") |
| Hip fracture | After low-energy fall; severe morbidity and mortality in elderly (20-30% mortality at 1 year) |
| Wrist (Colles') fracture | Falling on outstretched hand |
| Rib fractures | After minimal trauma or coughing |
Red Flags for Vertebral Fractures
- Fractures above T7: think metastases (osteoporotic fractures rare above T7)
- Posterior vertebral body fracture: think metastases or myeloma (not typical of osteoporosis)
- Pain that does NOT resolve in 6-8 weeks: metastases vs. osteoporosis
Diagnosis
| Test | Findings / Details |
|---|
| DXA scan | Gold standard; measures BMD at lumbar spine and hip; T-score defines severity |
| X-ray | Decreased bone density visible only when >30-40% bone mass lost; vertebral fractures (wedge, biconcave, crush) |
| FRAX tool | WHO tool; calculates 10-year probability of hip or major osteoporotic fracture; accounts for age, BMI, prior fracture, smoking, alcohol, steroids, RA |
| Blood tests | Ca, phosphate, ALP, 25-OH vitamin D, PTH, thyroid function, LH/FSH, testosterone (to identify secondary causes) |
| CT scan | Vertebral fracture quantification; shows trabecular rarefaction |
DEXA scan demonstrating osteoporosis:
DEXA scan report: T-score -5.1 at lumbar spine, -3.8 at hip - well into the osteoporosis range (threshold: -2.5). The fracture risk graph shows data in the high-risk zone.
Treatment of Osteoporosis
Non-Pharmacological (For ALL Patients)
| Approach | Recommendation |
|---|
| Calcium | At least 1200 mg/day (diet + supplement combined) |
| Vitamin D | 800-2000 IU/day; target 25-OH vitamin D >30 ng/mL to ensure adequate calcium absorption |
| Weight-bearing exercise | Walking, jogging, dancing; stimulates osteoblast activity and bone formation |
| Fall prevention | Remove home hazards, balance training, vision correction, review medications causing dizziness |
| Smoking cessation | Smoking accelerates bone loss |
| Reduce alcohol | >3 units/day increases fracture risk |
| Treat underlying causes | Correct vitamin D deficiency, manage thyroid disease, minimize glucocorticoid dose |
Pharmacological - Anti-Resorptive Agents
| Drug | Class | Mechanism | Evidence |
|---|
| Alendronate (10 mg/day or 70 mg/week) | Bisphosphonate | Inhibits osteoclast function; reduces bone resorption | Gold standard; reduces vertebral, hip, and non-vertebral fractures |
| Risedronate (5 mg/day or 35 mg/week) | Bisphosphonate | Same as above | Reduces vertebral, hip fractures |
| Zoledronic acid (5 mg IV/year) | IV Bisphosphonate | Once-yearly IV; better compliance | Superior to oral bisphosphonates in some studies |
| Denosumab (60 mg SC every 6 months) | RANK-L inhibitor monoclonal antibody | Inhibits osteoclast formation and activity | Reduces hip, vertebral, and non-vertebral fractures; useful when bisphosphonates contraindicated |
| Raloxifene (60 mg/day) | SERM | Estrogen receptor modulator; inhibits bone resorption | Reduces vertebral fractures (not hip); also reduces breast cancer risk |
| Calcitonin | Hormone | Inhibits osteoclast activity; mild analgesic effect | Modest anti-fracture efficacy; useful for vertebral fracture pain relief |
| Estrogen/HRT | Hormone replacement | Inhibits bone resorption | For postmenopausal women who also have menopausal symptoms; increased breast/CVD risk |
Pharmacological - Anabolic (Bone-Building) Agents
| Drug | Class | Mechanism | Evidence |
|---|
| Teriparatide (20 mcg SC/day) | PTH analogue (PTH 1-34) | Stimulates osteoblast activity; builds new bone | Reduces vertebral AND non-vertebral fractures; for severe osteoporosis; max 2 years |
| Abaloparatide | PTHrP analogue | Anabolic; stimulates bone formation | Reduces vertebral and non-vertebral fractures |
| Romosozumab (210 mg SC/month) | Anti-sclerostin antibody | Dual action: stimulates bone formation + reduces resorption | Most potent BMD gain; followed by bisphosphonate to consolidate gains |
From Swanson's Family Medicine: "Bisphosphonates - demonstrated efficacy for vertebral fracture reduction; alendronate and risedronate for non-vertebral and hip fracture reduction as well."
Teriparatide and denosumab - both demonstrated efficacy for vertebral AND non-vertebral fracture reduction.
Surgical Options (for Fractures)
| Procedure | Indication |
|---|
| Vertebroplasty | Cement injection into fractured vertebral body for persistent pain; performed within 4-6 weeks of fracture onset |
| Balloon kyphoplasty | Balloon creates cavity first, then cement fills; restores vertebral height + relieves pain |
| Hip fracture surgery | Hemiarthroplasty or total hip replacement for femoral neck fractures; internal fixation for intertrochanteric fractures |
From Grainger & Allison's Diagnostic Radiology: "Patients with proven osteoporosis should always be commenced on bone protective/bone enhancing therapy when vertebroplasty is performed."
SIDE-BY-SIDE COMPARISON TABLE
| Feature | Osteoarthritis | Osteoporosis |
|---|
| Type of disease | Degenerative joint disease | Metabolic bone disease |
| Tissue involved | Articular cartilage, subchondral bone, synovium | Trabecular and cortical bone (whole skeleton) |
| Mechanism | Cartilage degeneration > repair | Bone resorption > formation |
| Age of onset | Usually >50 | Peak loss post-menopause; fractures from 60s+ |
| Sex predominance | Women (especially hands, knees) | Women >> Men (postmenopausal estrogen loss) |
| Symptoms | Joint pain, stiffness, crepitus, deformity | Asymptomatic until fracture |
| Pain type | Mechanical (worse with activity) | Fracture pain (acute, severe) |
| Morning stiffness | <30 minutes | None (unless fracture) |
| Inflammation | Mild/secondary | None |
| Systemic effects | None | None (until fracture complications) |
| Joints affected | Hips, knees, spine, finger joints | Any bone (spine, hip, wrist most common) |
| X-ray findings | Joint space narrowing, osteophytes, sclerosis, cysts | Decreased bone density, vertebral wedge/crush fractures |
| Key investigation | X-ray | DXA scan (T-score) |
| Blood tests | Normal | Normal (unless secondary cause) |
| Key drug treatment | NSAIDs, analgesics, intra-articular steroids | Bisphosphonates, calcium, vitamin D |
| Curative surgery | Joint replacement (arthroplasty) | Vertebroplasty / fracture fixation (palliative) |
| Prevention | Weight loss, exercise, joint protection | Calcium, vitamin D, weight-bearing exercise, fall prevention |
| Can they coexist? | YES - same patient can have both simultaneously | |
A Note on Co-existence
A single patient (typically an elderly postmenopausal woman) can have both OA and osteoporosis at the same time. OA mainly affects the joints (causing pain and stiffness), while osteoporosis affects bone density (causing fracture risk). Treating one does not treat the other - they need separate management strategies.
Sources: Robbins & Kumar Basic Pathology; Goldman-Cecil Medicine International Edition; Bailey and Love's Short Practice of Surgery 28th Ed; Swanson's Family Medicine Review; Grainger & Allison's Diagnostic Radiology; Firestein & Kelley's Textbook of Rheumatology; Rosen's Emergency Medicine 9e